Anavex Life Sciences Corp (AVXL)

[georgejjl]

The following projection of revenue in the EU alone for blarcamesine is very promising:

“..,The EU is home to 7 or 8 million AD patients. If the EU were willing to spend $10,000 each for 3 million AD patients annually, that amounts to a $30 billion price tag, translating to $30 billion or so in revenues for Anavex Life Sciences.
Is there price elasticity for an AD drug? Let's say the price tag is only $5000, and it's purchased for 8 million AD patients. That produces a $40 billion annual revenue stream.
The company is currently valued at about $800 million. Without product price information, I would expect the value of the company to increase immediately to between $8 billion and $16 billion, if and when the EU approves Blarcamesine for the treatment of people with MCI or early-stage dementia as a result of Alzheimer's Disease….”

Good luck and GOD bless,